Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 March 2015Website:
http://www.summittxinc.comNext earnings report:
20 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:59:46 GMTDividend
Analysts recommendations
Institutional Ownership
SMMT Latest News
A cancer drug has vast potential for the company, says a pundit newly following it.
JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones.
SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and CEO Maky Zanganeh - CEO and President Manmeet Soni - COO and CFO Allen Yang - Chief Medical Officer Conference Call Participants Mitchell Kapoor - H. C. Wainwright Brad Canino - Stifel Yigal Nochomovitz - Citi Operator Good morning.
The potential upside of this stock is undeniably meaty.
This drugmaker's lead candidate could become a top-selling cancer therapy.
Millennium Management just initiated a position in a small biotech company developing a new cancer drug.
The shares have experienced a pullback in the past couple of weeks.
It's hard to go wrong with either company, but one is more appealing.
It's easier to invest confidently when you know both the pros and the cons in full.
What type of business is Summit Therapeutics?
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
What sector is Summit Therapeutics in?
Summit Therapeutics is in the Healthcare sector
What industry is Summit Therapeutics in?
Summit Therapeutics is in the Biotechnology industry
What country is Summit Therapeutics from?
Summit Therapeutics is headquartered in United States
When did Summit Therapeutics go public?
Summit Therapeutics initial public offering (IPO) was on 05 March 2015
What is Summit Therapeutics website?
https://www.summittxinc.com
Is Summit Therapeutics in the S&P 500?
No, Summit Therapeutics is not included in the S&P 500 index
Is Summit Therapeutics in the NASDAQ 100?
No, Summit Therapeutics is not included in the NASDAQ 100 index
Is Summit Therapeutics in the Dow Jones?
No, Summit Therapeutics is not included in the Dow Jones index
When was Summit Therapeutics the previous earnings report?
No data
When does Summit Therapeutics earnings report?
The next expected earnings date for Summit Therapeutics is 20 February 2025